Skip to content

TuHURA Biosciences, Inc. HURA Deferred Offering Costs Not Yet Paid

Deferred Offering Costs Not Yet Paid at other companies

NTS
Netskope, Inc. Class A Common StockNTSK
$0-100%
ALO
Aldabra 4 Liquidity Opportunity Vehicle ALOV
$163.78K
KRAKacquisition
 logo
KRAKacquisition KRAQ
$328.39K
STU
StubHub Holdings, Inc.STUB
$352K-95.0%
XSL
Xsolla XSLL
$75K
HVI
Hennessy Capital Investment Corp. VII Ordinary SharesHVII
$456.06K

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept hura:DeferredOfferingCostsNotYetPaid.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s deferred offering costs not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s deferred offering costs not yet paid?
TuHURA Biosciences, Inc. (HURA) reported deferred offering costs not yet paid of $314.17K in Q1 2026.
How has TuHURA Biosciences, Inc.'s deferred offering costs not yet paid changed year-over-year?
TuHURA Biosciences, Inc.'s deferred offering costs not yet paid increased by 2149.7% year-over-year, from $13.97K to $314.17K.
What does deferred offering costs not yet paid mean?
Reflects costs incurred in connection with a securities offering that have been recognized but remain unpaid at the end of the reporting period. This serves as a measure of short-term accrued liabilities specifically tied to capital raising activities.